Vis enkel innførsel

dc.contributor.authorKarlsvik, Tina Margrethe
dc.contributor.authorBorgenvik, Thore Langfeldt
dc.contributor.authorAadalen, Mirjam
dc.contributor.authorUtne, Kristin Kornelia
dc.contributor.authorFørsund, Eli
dc.contributor.authorJørgensen, Camilla Tøvik
dc.contributor.authorHolst, René
dc.contributor.authorJelsness-Jørgensen, Lars-Petter
dc.contributor.authorGhanima, Waleed Khalid
dc.date.accessioned2020-08-28T12:54:24Z
dc.date.available2020-08-28T12:54:24Z
dc.date.created2020-03-09T13:47:03Z
dc.date.issued2020-03-09
dc.identifier.citationResearch and Practice in Thrombosis and Haemostasis. 2020, 4 (4), 582-585.en_US
dc.identifier.issn2475-0379
dc.identifier.urihttps://hdl.handle.net/11250/2675558
dc.description.abstractBackground Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has been observed in clinical practice, but data on this potential side effect are lacking. Objective The study aimed to evaluate development of fatigue in patients treated for VTE, comparing rivaroxaban to other anticoagulants. Methods Patients were prospectively recruited after a diagnosis of VTE. The Fatigue Questionnaire was used to determine the level of fatigue at baseline, at 3 weeks of treatment, and either at 1 month after the discontinuation of treatment if the treatment was discontinued after 3 months or at 6 months if treatment was continued beyond this time. Data was analyzed by a linear mixed model. Results A total of 126 patients were included. Mean age was 59 years; 77 (61%) were males. Fifty‐seven patients (45%) were diagnosed with deep vein thrombosis, 48 (38%) with pulmonary embolism, and 21 (17%) with both. Predicted changes in fatigue scores from baseline to the last measurement were −0.007 and −2.49 for the rivaroxaban and the other‐anticoagulants groups, respectively, neither of which were statistically significant. No difference was detected between rivaroxaban and the other‐anticoagulants group at any time point, including subgroup analysis comparing over and under 6 months of treatment duration. Conclusion In this small study, our results suggest no increase in the level of fatigue after the initiation of treatment with rivaroxaban for VTE.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectanticoagulantsen_US
dc.subjectfatigueen_US
dc.subjectpulmonary embolismen_US
dc.subjectrivaroxabanen_US
dc.subjectthrombosisen_US
dc.subjectvenous thromboembolismen_US
dc.subjectvenous thrombosisen_US
dc.titleFatigue after initiating rivaroxaban for venous thromboembolismen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kar- og thoraxkirurgi: 782en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Lungesykdommer: 777en_US
dc.source.pagenumber582-585en_US
dc.source.volume4en_US
dc.source.journalResearch and Practice in Thrombosis and Haemostasisen_US
dc.source.issue4en_US
dc.identifier.doi10.1002/rth2.12312
dc.identifier.cristin1800648
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal